Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in use of clinical pathways.
Adam Boehler, former director of the Center for Medicare and Medicare Innovation (CMMI), and Kavita Patel, MD, a senior health policy advisor to former President Barrack Obama, will each deliver remarks focused on the future of healthcare and value-based care.
Key stakeholders involved in the delivery of cancer care in New Jersey discuss strategies driving innovation in oncology and remaining challenges impeding their integration at the 70th Annual Roy A. Bowers Pharmaceutical Conference.
The abstracts address the latest research addressing clinical innovation, care delivery, health equity, clinical trial diversity, measuring patient and caregiver experience, provider efficiency, clinical outcomes, quality care, and safety in oncology.
Each disease group guides and approves OneOncology clinical pathways to reflect evidenced-based national guidelines, which are updated often as new trial results are published or presented at major scientific meetings.
The Institute of Value-Based Medicine® (IVBM), hosted by Tennessee Oncology, brought health care leaders together on April 21 in Nashville, Tennessee, to discuss oncology care delivery—and to see colleagues in person, some for the first time since 2020.
After the Oncology Care Model (OCM) expires at the end of June, Tennessee Oncology will take what it learned from the model and apply it to commercial value-based care arrangements and potentially the next Medicare model, said Leah Owens, DNP, RN, executive director of care transformation at Tennessee Oncology.
Stephen M. Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, previews the Nashville meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by Tennessee Oncology.
Davey Daniel, MD, chief medical officer, OneOncology, speaks on the knowledge, infrastructure, and payer-related barriers that are limiting the use of genomic testing in the management of patients with lung cancer.